These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 124232)

  • 1. Urinary kallikrein excretion in essential and mineralocorticoid hypertension.
    Holland OB; Chud JM; Braunstein H
    J Clin Invest; 1980 Feb; 65(2):347-56. PubMed ID: 7356684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo.
    Mendelsohn FA; Lloyd CJ; Kachel C; Funder JW
    J Clin Invest; 1982 Sep; 70(3):684-92. PubMed ID: 6286730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-renin hypertension of childhood.
    DiMartino-Nardi J; New MI
    Pediatr Nephrol; 1987 Jan; 1(1):99-108. PubMed ID: 3153266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the mineralocorticoid and hypertensogenic properties of 16beta-hydroxy-dehydroepiandrosterone.
    Gomez-Sanchez C; Holland OB; Hall CE; Ayachi S
    Experientia; 1976 Aug; 32(8):1067-9. PubMed ID: 182526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of 16beta-hydroxydehydroepiandrosterone with renal mineralocorticoid receptors.
    Higgins JR; Wambach G; Kem DC; Gomez-Sanchez C; Holland OB; Kaplan NM
    J Lab Clin Med; 1977 Feb; 89(2):250-6. PubMed ID: 137938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid activity of 16beta-hydroxydehydroepiandrosterone and related steroids.
    Gomez-Sanchez C; Holland OB; Higgins JR; Mathieu R; Gruber GM; Milewich L; Kaplan NM
    J Lab Clin Med; 1976 Oct; 88(4):571-7. PubMed ID: 135037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 16Beta-hydroxydehydroepiandrosterone: the dichotomy between renal receptor binding and urinary electrolyte activity.
    Funder JW; Robinson JA; Feldman D; Wynne KN; Adam WR
    Endocrinology; 1976 Aug; 99(2):619-28. PubMed ID: 182463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure changes following chronic administration to rats of 3beta,16beta-dihydroxy-5-androsten-17-one, 3beta,17beta-dihydroxy-5-androsten-16-one and 21-hydroxy-4-pregnene-3,20-dione-21-acetate.
    Ogihara T; Ichihara K; Yamamoto T; Kumahara Y; Kircher HW; Nugent CA
    Steroids; 1977 Jan; 29(1):17-20. PubMed ID: 138980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a new mineralocorticoid in patients with low-renin essential hypertension.
    Sennett JA; Brown RD; Island DP; Yarbro LR; Watson JT; Slaton PE; Hollifield JW; Liddle GW
    Circ Res; 1975 Jun; 36(6 Suppl 1):2-9. PubMed ID: 124232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New mineralocorticoids and adrenocorticosteroids in hypertension.
    Melby JC; Dale SL
    Am J Cardiol; 1976 Nov; 38(6):805-13. PubMed ID: 136892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess.
    Beevers DG; Brown JJ; Ferriss JB; Fraser R; Lever AF; Robertson JI
    Am Heart J; 1973 Sep; 86(3):404-14. PubMed ID: 4592546
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.